Not only do clinical studies support the direct involvement of xanthine oxidation pathway in HF progression, but they also suggest xanthine oxidase as novel therapeutic target and better therapy, which potentially leads to improve myocardial efficiency [43,44]. This evidence concerns the gene XDH and hydrops fetalis.